Last reviewed · How we verify
NCT06668441
Minimally Invasive Surgery and rhTNK-tPA for Intracerebral Hemorrhage Evacuation
Phase 1 trial testing Minimally invasive surgery plus low-dose rhTNK-tPA group in Intracranial Hemorrhages in 12 participants. Completed in 27 January 2025.
27 January 2025
Quick facts
| Lead sponsor | Beijing Tiantan Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 4 November 2024 |
| Primary completion | 27 January 2025 |
| Estimated completion | 27 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Minimally invasive surgery plus low-dose rhTNK-tPA group — full drug profile →
- Minimally invasive surgery plus medium dose rhTNK-tPA group — full drug profile →
- Minimally invasive surgery plus high dose rhTNK-tPA group — full drug profile →
Conditions studied
- Intracranial Hemorrhages — all drugs for Intracranial Hemorrhages →
- Cerebrovascular Disorders — all drugs for Cerebrovascular Disorders →
- Cerebral Hemorrhage — all drugs for Cerebral Hemorrhage →
- Hemorrhage — all drugs for Hemorrhage →
Sponsor
Beijing Tiantan Hospital
Who can join
Adults 18 to 80, any sex, with Intracranial Hemorrhages or Cerebrovascular Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this trial is to determine the safety of using a combination of robot-assisted stereotactic puncture and clot lysis with rhTNK-tPA to remove intracerebral hemorrhage (ICH) and to provide dose evidence for a phase III clinical trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Phase I dose-escalation study of tenecteplase, a third-generation fibrinolytic agent, combined with neuronavigation-assisted stereotactic minimally invasive puncture, in patients with acute spontaneous deep cerebral haemorrhage.
Wu Z, Wang M, Bai X, Tang J, et al · · 2025 · PMID 40992931 · DOI 10.1136/svn-2025-004389
Verify or expand the search:
- PubMed search for NCT06668441
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intracranial Hemorrhages
Currently open trials in the same condition.
- NCT06878066 — Thrombolysis in Factor Xa-inhibitors Trial · Phase 3 · recruiting
- NCT07175519 — Safety and Efficacy of Aneurysms Treated With Endovascular Devices · recruiting
- NCT06632587 — Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes · NA · recruiting
- NCT06635564 — Personalized ViscoElastic Testing-guided Bleeding Management In Liver Surgery, Neurosurgery and Obstetrics · recruiting
- NCT06404645 — A Clinical Prospective Observational Study of Near Infrared Spectroscopy to Detect Subcranial Hematoma · recruiting
Other Beijing Tiantan Hospital trials
Trials by the same sponsor.
- NCT07341854 — Dexamethasone Palmitate for Postoperative Pain · NA · not yet recruiting
- NCT07527013 — Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07520370 — Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor · NA · not yet recruiting
- NCT07526987 — Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis · Phase 3 · not yet recruiting
- NCT07591207 — The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06668441 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tiantan Hospital
- Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06668441.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing